BR112012006088A2 - métodos para caracterizar um paciente como respondedor ou não respondedor a uma terapia, para tratar um paciente, para determinar se um paciente é um respondedor ou um não respondedor a uma imunoterapêutica, uso de uma lista de gene, microarranjo, kit de diagnostic, composição, uso de uma composição, e, superfície sólida - Google Patents

métodos para caracterizar um paciente como respondedor ou não respondedor a uma terapia, para tratar um paciente, para determinar se um paciente é um respondedor ou um não respondedor a uma imunoterapêutica, uso de uma lista de gene, microarranjo, kit de diagnostic, composição, uso de uma composição, e, superfície sólida Download PDF

Info

Publication number
BR112012006088A2
BR112012006088A2 BR112012006088-0A BR112012006088A BR112012006088A2 BR 112012006088 A2 BR112012006088 A2 BR 112012006088A2 BR 112012006088 A BR112012006088 A BR 112012006088A BR 112012006088 A2 BR112012006088 A2 BR 112012006088A2
Authority
BR
Brazil
Prior art keywords
genes
gene
patient
responder
identified
Prior art date
Application number
BR112012006088-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Vincent Brichard
Benjamin Georges Elie Lea Ghislain Dizier
Oliver Gruselle
Jamila Louahed
Fernando Ulloa-Montoya
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of BR112012006088A2 publication Critical patent/BR112012006088A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112012006088-0A 2009-09-18 2010-09-17 métodos para caracterizar um paciente como respondedor ou não respondedor a uma terapia, para tratar um paciente, para determinar se um paciente é um respondedor ou um não respondedor a uma imunoterapêutica, uso de uma lista de gene, microarranjo, kit de diagnostic, composição, uso de uma composição, e, superfície sólida BR112012006088A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US27704609P 2009-09-18 2009-09-18
US61/277046 2009-09-18
US27838709P 2009-10-06 2009-10-06
US61/278387 2009-10-06
GB0917457.4 2009-10-06
GBGB0917457.4A GB0917457D0 (en) 2009-10-06 2009-10-06 Method
PCT/EP2010/063751 WO2011033095A1 (en) 2009-09-18 2010-09-17 Method for identifying whether a patient will be responder or not to immunotherapy

Publications (1)

Publication Number Publication Date
BR112012006088A2 true BR112012006088A2 (pt) 2020-08-11

Family

ID=41393894

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012006088-0A BR112012006088A2 (pt) 2009-09-18 2010-09-17 métodos para caracterizar um paciente como respondedor ou não respondedor a uma terapia, para tratar um paciente, para determinar se um paciente é um respondedor ou um não respondedor a uma imunoterapêutica, uso de uma lista de gene, microarranjo, kit de diagnostic, composição, uso de uma composição, e, superfície sólida

Country Status (14)

Country Link
US (1) US20110070268A1 (https=)
EP (1) EP2478116A1 (https=)
JP (1) JP2013505008A (https=)
KR (1) KR20130055553A (https=)
CN (1) CN102597269A (https=)
AU (1) AU2010297248A1 (https=)
BR (1) BR112012006088A2 (https=)
CA (1) CA2773666A1 (https=)
EA (1) EA201290107A1 (https=)
GB (1) GB0917457D0 (https=)
IL (1) IL218313A0 (https=)
MX (1) MX2012003329A (https=)
SG (1) SG179129A1 (https=)
WO (1) WO2011033095A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11021752B2 (en) 2013-03-15 2021-06-01 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
EP3164508B1 (en) 2014-07-02 2023-06-07 Myriad myPath, LLC Genes and gene signatures for diagnosis and treatment of melanoma
JP2018503373A (ja) * 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
AU2017261353A1 (en) * 2016-05-05 2018-11-08 Nantomics, Llc Checkpoint failure and methods therefor
KR102169901B1 (ko) * 2019-05-17 2020-10-26 연세대학교 산학협력단 Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
AU2021237626A1 (en) * 2020-03-17 2022-11-10 Regeneron Pharmaceuticals, Inc. Methods and systems for determining responders to treatment
EP4161658A4 (en) * 2020-06-01 2024-10-02 Dana-Farber Cancer Institute, Inc. Methods for modulating mhc-i expression and immunotherapy uses thereof
CN115495026B (zh) * 2022-11-21 2023-03-10 杭州字节方舟科技有限公司 一种优化内存处理方法、装置、设备及存储介质

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
CZ298364B6 (cs) 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
PT1104306E (pt) 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
CZ20012587A3 (cs) 1999-01-29 2002-05-15 Corixa Corporation Izolovaný protein, nukleová kyselina, virový vektor, farmaceutický prostředek, izolovaná populace T buněk, způsob posílení imunitní odpovědi, způsob odstranění nádorových buněk, způsob stimulace a/nebo namnoľení T buněk a způsob přípravy fúzního proteinu
PT1165778E (pt) 1999-03-11 2007-01-31 Glaxosmithkline Biolog Sa Utilizações de polinucleótidos e polipéptidos casb618
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
IL151097A0 (en) 2000-02-23 2003-04-10 Smithkline Beecham Biolog Tumour-specific animal proteins
US20020076469A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
DE10127572A1 (de) * 2001-05-30 2002-12-05 Pathoarray Gmbh Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
WO2003050257A2 (en) * 2001-12-06 2003-06-19 University Of Florida Targeting leukemia cells
DE60234386D1 (de) 2002-02-04 2009-12-24 Corixa Corp Neue immuneffektor-verbindungen
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
KR20050010040A (ko) 2002-06-11 2005-01-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004076565A2 (en) * 2003-02-25 2004-09-10 Technical Knockout, Inc. Improved coated weight plates, dumbbells and method of manufacture
US20040191819A1 (en) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corporation Expression profiles for breast cancer and methods of use
US20050095607A1 (en) * 2003-03-07 2005-05-05 Arcturus Bioscience, Inc. University Of Louisville Breast cancer signatures
WO2004081564A1 (en) 2003-03-14 2004-09-23 Peter Maccallum Cancer Institute Expression profiling of tumours
US20040241725A1 (en) * 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
US7598287B2 (en) * 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
AU2004248120B2 (en) * 2003-05-28 2009-04-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA2527680A1 (en) 2003-05-30 2005-06-02 Astrazeneca Uk Limited Markers for responsiveness to an erbb receptor tyrosine kinase inhibitor
WO2005001138A2 (en) * 2003-06-18 2005-01-06 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
ATE403755T1 (de) * 2003-08-28 2008-08-15 Ipsogen Identifizierung einer erbb2- genexpressionssignatur bei brustkrebs
WO2005032495A2 (en) * 2003-10-03 2005-04-14 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
US20070110710A1 (en) * 2003-11-05 2007-05-17 New England Medical Center Hospitals, Inc. Treatment with immunoregulatory t cells
EP1721991B1 (en) * 2004-02-09 2015-09-30 Fuso Pharmaceutical Industries Ltd. Method of detecting nucleic acid and utilization thereof
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
US20070237717A1 (en) * 2004-04-05 2007-10-11 Roland Martin Methods for Selection of Subjects for Multiple Sclerosis Therapy
US7332281B2 (en) * 2004-04-27 2008-02-19 Sagres Discovery, Inc. Therapeutic targets in cancer
CA2587676A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
CA2589782A1 (en) * 2004-11-30 2006-06-08 Veridex Llc Lung cancer prognostics
US20070059720A9 (en) * 2004-12-06 2007-03-15 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients
US7666595B2 (en) * 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
GB0504302D0 (en) 2005-03-02 2005-04-06 Univ Dublin Markers for melanoma
WO2006103442A2 (en) 2005-04-01 2006-10-05 Ncc Technology Ventures Pte. Ltd. Materials and methods relating to breast cancer classification
CA2608359A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
US20070111257A1 (en) * 2005-07-07 2007-05-17 Kohne David E Improved protein expression comparison assay results and applications
CA2650507A1 (en) * 2006-04-27 2007-11-08 Universite De Montreal Assessment and reduction of risk of graft-versus-host disease
WO2007140958A2 (en) * 2006-06-02 2007-12-13 Glaxosmithkline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy
WO2009034055A1 (en) * 2007-09-10 2009-03-19 Novartis Forschungsstiftung, Zweigniederlassung Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy
EP2227558A1 (en) * 2007-11-30 2010-09-15 GlaxoSmithKline Biologicals SA Method for classifying cancer patients as responder or non-responder to immunotherapy

Also Published As

Publication number Publication date
EA201290107A1 (ru) 2012-10-30
AU2010297248A1 (en) 2012-04-12
CN102597269A (zh) 2012-07-18
GB0917457D0 (en) 2009-11-18
JP2013505008A (ja) 2013-02-14
US20110070268A1 (en) 2011-03-24
WO2011033095A1 (en) 2011-03-24
MX2012003329A (es) 2012-04-20
CA2773666A1 (en) 2011-03-24
EP2478116A1 (en) 2012-07-25
IL218313A0 (en) 2012-04-30
SG179129A1 (en) 2012-05-30
KR20130055553A (ko) 2013-05-28

Similar Documents

Publication Publication Date Title
BR112012006088A2 (pt) métodos para caracterizar um paciente como respondedor ou não respondedor a uma terapia, para tratar um paciente, para determinar se um paciente é um respondedor ou um não respondedor a uma imunoterapêutica, uso de uma lista de gene, microarranjo, kit de diagnostic, composição, uso de uma composição, e, superfície sólida
JP5009787B2 (ja) Ｅｒｇ遺伝子を単独でまたは前立腺癌中で過剰発現もしくは過少発現される他の遺伝子と組み合わせて用いる、前立腺癌を診断または治療する方法
BRPI0712497A2 (pt) perfil de gene, uso de um perfil, método para identificar um perfil, usos de uma sonda e de um kit de microarranjo para a identificação da expressão diferencial de pelo menos um produto de gene de ativação imune, microarranjo, kit de diagnóstico, e, método para tratar um paciente, e para induzir um perfil de gene respondedor em paciente distinguido como um não respondedor.
KR101437718B1 (ko) 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
US20100247580A1 (en) Method for Classifying Cancer Patients as Responder or Non-Responder to Immunotherapy
EP2309273B1 (en) Novel tumor marker determination
US20190048422A1 (en) Compositions and methods for detecting and diagnosing neoplasia
CN101932723A (zh) 改进的对mage-a表达的检测
CA2742489A1 (en) Methods for identification of tumor phenotype and treatment
JP2009539404A (ja) 大腸癌の早期検出および予後のためのメチル化マーカー
CN102575284A (zh) 改进的基因表达检测
Luoh Amplification and expression of genes from the 17q11∼ q12 amplicon in breast cancer cells
CN117916596A (zh) 生物流体中靶分子的分析方法
CN105659085A (zh) 预测受试者对多激酶抑制剂的反应的基因表达标志及其使用方法
CN114222583A (zh) 用于治疗乳癌/乳腺癌的i类和ii类hla肿瘤抗原肽
WO2014074785A1 (en) Methods of predicting outcome and treating breast cancer
Desai et al. Chipping away at breast cancer: insights from microarray studies of human and mouse mammary cancer.
CN107236816A (zh) Ddr2突变作为黑素瘤或基底细胞癌的可靶向的特征
JP5705191B2 (ja) Ｍａｇｅ−ａ３マーカーの特異的検出のためのプライマーおよびプローブを含む癌の検出および診断の方法
EP3229830B1 (en) Methods of treating and prognosing nonhematopoietic malignant tumors
Abramovitz et al. Application of array-based genomic and epigenomic technologies to unraveling the heterogeneous nature of breast tumors: on the road to individualized treatment
WO2023129460A2 (en) Tumor mhc class i expression is associated with interleukin-2 response in melanoma
US20100166783A1 (en) Method
Tanvetyanon et al. Current Clinical Application of Genomic and Proteomic Profiling in Non—Small-Cell Lung Cancer
Jiang et al. The Immune Landscape of Acral Melanoma: From Basic to Clinical

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2598 DE 20-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]